日本内阁官房长官木原稔：正以高度紧迫感密切关注市场动向。

Moderna raised its full-year revenue guidance to growth of 15–25% (up from prior 10%) and reported its first quarterly profit since 2024, driven by a sharp year‑on‑year rebound in COVID‑19 vaccine sales; third‑quarter results beat a Street consensus that had forecast a loss. The company is shifting toward oncology; its Merck‑partnered mRNA skin‑cancer vaccine intismeran posted positive late‑stage trial results, and Moderna said the drug could win US approval next year — an outcome it called an important breakthrough for its mRNA platform. Moderna shares have rallied more than 700% YTD through Thursday.

India's NIFTY Financial Services Index rose 1.1%.